1
|
Garraway IP, Carlsson SV, Nyame YA, Vassy JL, Chilov M, Fleming M, Frencher SK, George DJ, Kibel AS, King SA, Kittles R, Mahal BA, Pettaway CA, Rebbeck T, Rose B, Vince R, Winn RA, Yamoah K, Oh WK. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM EVIDENCE 2024; 3:EVIDoa2300289. [PMID: 38815168 DOI: 10.1056/evidoa2300289] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2024]
Abstract
BACKGROUND In the United States, Black men are at highest risk for being diagnosed with and dying from prostate cancer. Given this disparity, we examined relevant data to establish clinical prostate-specific antigen (PSA) screening guidelines for Black men in the United States. METHODS A comprehensive literature search identified 1848 unique publications for screening. Of those screened, 287 studies were selected for full-text review, and 264 were considered relevant and form the basis for these guidelines. The numbers were reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. RESULTS Three randomized controlled trials provided Level 1 evidence that regular PSA screening of men 50 to 74 years of age of average risk reduced metastasis and prostate cancer death at 16 to 22 years of follow-up. The best available evidence specifically for Black men comes from observational and modeling studies that consider age to obtain a baseline PSA, frequency of testing, and age when screening should end. Cohort studies suggest that discussions about baseline PSA testing between Black men and their clinicians should begin in the early 40s, and data from modeling studies indicate prostate cancer develops 3 to 9 years earlier in Black men compared with non-Black men. Lowering the age for baseline PSA testing to 40 to 45 years of age from 50 to 55 years of age, followed by regular screening until 70 years of age (informed by PSA values and health factors), could reduce prostate cancer mortality in Black men (approximately 30% relative risk reduction) without substantially increasing overdiagnosis. CONCLUSIONS These guidelines recommend that Black men should obtain information about PSA screening for prostate cancer. Among Black men who elect screening, baseline PSA testing should occur between ages 40 and 45. Depending on PSA value and health status, annual screening should be strongly considered. (Supported by the Prostate Cancer Foundation.).
Collapse
Affiliation(s)
- Isla P Garraway
- Department of Urology, David Geffen School of Medicine, University of California and Department of Surgical and Perioperative Care, VA Greater Los Angeles Healthcare System, Los Angeles
| | - Sigrid V Carlsson
- Departments of Surgery and Epidemiology and Biostatistics, Urology Service, Memorial Sloan Kettering Cancer Center, New York
- Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, and Department of Translational Medicine, Division of Urological Cancers, Medical Faculty, Lund University, Lund, Sweden
| | - Yaw A Nyame
- Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle
- Department of Urology, University of Washington, Seattle
| | - Jason L Vassy
- Center for Healthcare Organization and Implementation Research (CHOIR), Veterans Health Administration, Bedford and Boston
- Harvard Medical School and Brigham and Women's Hospital, Boston
| | - Marina Chilov
- Medical Library, Memorial Sloan Kettering Cancer Center, New York
| | - Mark Fleming
- Virginia Oncology Associates, US Oncology Network, Norfolk, VA
| | - Stanley K Frencher
- Martin Luther King Jr. Community Hospital and University of California, Los Angeles
| | - Daniel J George
- Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC
| | - Adam S Kibel
- Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Sherita A King
- Section of Urology, Medical College of Georgia at Augusta University and Charlie Norwood Veterans Affairs Medical Center, Augusta, GA
| | - Rick Kittles
- Morehouse School of Medicine, Community Health and Preventive Medicine, Atlanta
| | - Brandon A Mahal
- Sylvester Comprehensive Cancer Center, Miami
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami
| | - Curtis A Pettaway
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston
| | - Timothy Rebbeck
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
- Harvard T.H. Chan School of Public Health, Boston
| | - Brent Rose
- Department of Radiation Oncology, University of California, San Diego
- Veterans Affairs San Diego Healthcare System, San Diego, CA
| | - Randy Vince
- Department of Urology, University of Michigan, Ann Arbor
| | - Robert A Winn
- Massey Cancer Center, Virginia Commonwealth University, Richmond
- Department of Internal Medicine, Virginia Commonwealth University, Richmond
| | - Kosj Yamoah
- Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
- James A. Haley Veterans' Hospital, Tampa, FL
| | - William K Oh
- Prostate Cancer Foundation, Santa Monica, CA
- Division of Hematology and Medical Oncology, Tisch Cancer Institute at Mount Sinai, New York
| |
Collapse
|
2
|
Palsdottir T, Nordstrom T, Karlsson A, Grönberg H, Clements M, Eklund M. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. BMJ Open 2019; 9:e027958. [PMID: 30928965 PMCID: PMC6475177 DOI: 10.1136/bmjopen-2018-027958] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 01/30/2019] [Accepted: 01/31/2019] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVE Given a man's current prostate- specific antigen (PSA) level, age and family history of prostate cancer, what are the benefits (decreased risk of higher Gleason score [GS] cancer at diagnosis) and harms (increased risk of false-positive biopsy recommendation) of waiting 1, 2, 3, 4 or 5-8 years until the next PSA test? DESIGN Prospective cohort. SETTING All PSA tested men in Stockholm, Sweden, between 2003 and 2015. PARTICIPANTS Men aged 50-74 years with at least two PSA tests between 2003 and 2015 (n=174 636). MAIN OUTCOME MEASURES Log-binomial regression to calculate the risk ratio (RR) of GS ≥7 and GS 6 versus benign outcome at prostate biopsy and 12-year cumulative probability of experiencing a false-positive biopsy by testing interval, age, PSA level and first-degree family history. RESULTS Men with PSA ≤1 ng/mL had low risk of GS ≥7 prostate cancer irrespective of testing interval; <3% had a PSA >3 at the next testing occasion, and of the 663 men biopsied after the next PSA test only 32 (5%) had GS ≥7 cancer. Men with PSA >1 ng/mL had increased risk of being diagnosed with GS ≥7 prostate cancer when screened with longer than annual intervals (RRs ranged from 1.4 to 3.2 depending on PSA level and testing interval). The results were consistent across age groups and family history status. This benefit needs to be balanced against the increased risk for false-positive biopsy recommendation with shorter testing intervals (twofold for annual vs biennial and threefold for annual vs triennial). CONCLUSIONS Men aged 50-74 years with PSA ≤1 ng/mL can wait 3-4 years before having a new PSA test. For men with PSA >1 ng/mL, we observed an increased risk of being diagnosed with GS ≥7 prostate cancer with longer than annual testing intervals. This benefit needs to be balanced against the markedly increased risks for false-positive biopsy recommendations with shorter testing intervals recommendations.
Collapse
Affiliation(s)
- Thorgerdur Palsdottir
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Tobias Nordstrom
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm S-182 88, Sweden
| | - Andreas Karlsson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Henrik Grönberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Oncology, Capio S:t Görans Sjukhus, Stockholm, Sweden
| | - Mark Clements
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Martin Eklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
Choi SK, Seel JS, Steck SE, Payne J, McCormick D, Schrock CS, Friedman DB. Talking About Your Prostate: Perspectives from Providers and Community Members. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2018; 33:1052-1060. [PMID: 28271389 PMCID: PMC5589476 DOI: 10.1007/s13187-017-1205-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Prostate cancer (PrCA) screening is controversial, especially for African-American (AA) men who have higher PrCA incidence and mortality than other racial/ethnic groups. Patient-provider communication is important for the PrCA screening decision process. The study purpose was to better understand the current dialogue between primary care providers (PCPs-physicians and nurse practitioners) and AA men about PrCA prevention and screening. An online survey with 46 PCPs, education sessions (including pre/post surveys) with 56 AA men, and a forum with 5 panelists and 38 AA men for open dialogue were held to examine both provider and community perspectives on PrCA communication needs and practices. PCPs' perceptions of PrCA screening were varied and they used different PrCA screening guidelines in their practices. PCPs and AA men had different experiences with PrCA communication. PCPs reported that they have discussions about PrCA screening and prostate health with AA patients; few AA men reported these same experiences. About 38.0% of PCPs reported that they remain neutral about PSA testing during discussions; however, only 10.7% of AA men reported that their doctor remained neutral. Prostate health knowledge among AA men increased significantly following participation in the education sessions (p < 0.001). AA community members reported high satisfaction regarding the education session and forum. Different recommendations from PCPs may hinder AA men's decisions about PrCA screening. The forum used in this study could be a model for others to help improve patient-provider communication and increase engagement in dialogue about this common cancer.
Collapse
Affiliation(s)
- Seul Ki Choi
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA
| | - Jessica S Seel
- Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA
| | - Susan E Steck
- Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA
- Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA
| | - Johnny Payne
- UsTOO Greenville and Upstate Prostate Cancer Alliance, 412 Perry Hill Road, Easley, SC, 29640, USA
| | - Douglas McCormick
- Greenville Health System Cancer Institute, 900 W Faris Rd, Greenville, SC, 29605, USA
| | - Courtney S Schrock
- Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA
| | - Daniela B Friedman
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA.
- Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA.
| |
Collapse
|
4
|
Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. Oncotarget 2018; 7:70388-70403. [PMID: 27611943 PMCID: PMC5342560 DOI: 10.18632/oncotarget.11865] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 08/13/2016] [Indexed: 12/22/2022] Open
Abstract
Genomic loss of chromosome (chr) 8p21 region, containing prostate-specific NKX3.1 gene, is a frequent alteration of the prostate cancer (PCa) oncogenome. We propose a novel, paradigm shifting hypothesis that this frequently deleted locus is also associated with a cluster of microRNA genes- miR-3622a/b- that are lost in PCa and play an important mechanistic role in progression and metastasis. In this study, we demonstrate the role of miR-3622b in prostate cancer. Expression analyses in a cohort of PCa clinical specimens and cell lines show that miR-3622b expression is frequently lost in prostate cancer. Low miR-3622b expression was found to be associated with tumor progression and poor biochemical recurrence-free survival. Further, our analyses suggest that miR-3622b expression is a promising prostate cancer diagnostic biomarker that exhibits 100% specificity and 66% sensitivity. Restoration of miR-3622b expression in PCa cell lines led to reduced cellular viability, proliferation, invasiveness, migration and increased apoptosis. miR-3622b overexpression in vivo induced regression of established prostate tumor xenografts pointing to its therapeutic potential. Further, we found that miR-3622b directly represses Epidermal Growth Factor Receptor (EGFR). In conclusion, our study suggests that miR-3622b plays a tumor suppressive role and is frequently downregulated in prostate cancer, leading to EGFR upregulation. Importantly, miR-3622b has associated diagnostic, prognostic and therapeutic potential. Considering the association of chr8p21 loss with poor prognosis, our findings are highly significant and support a novel concept that associates a long standing observation of frequent loss of a chromosomal region with a novel miRNA in prostate cancer.
Collapse
|
5
|
Abuadas MH, Petro-Nustas W, Albikawi ZF, Nabolsi M. Transcultural Adaptation and Validation of Champion's Health Belief Model Scales for Prostate Cancer Screening. J Nurs Meas 2017; 24:296-313. [PMID: 27535316 DOI: 10.1891/1061-3749.24.2.296] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Examining men's health beliefs regarding prostate cancer screening is a vital issue and requires a reliable and valid scale. PURPOSE Modify Champion's Revised Health Belief Model Scale to measure Jordanian men's beliefs about PCS, translate to Arabic, culturally adapt, and test its psychometric prosperities. METHOD This was a methodological study in which 432 healthy men were selected by convenient sampling. Analysis included estimation of content validity indices, internal consistency, construct validity, and predictive validity. RESULTS Exploratory factor analysis yielded seven significant factors which explained variance 68.9% of variance. Confirmatory factor analysis demonstrated that scale fit the data significantly. Cronbach's alpha coefficient ranged from .83 to .92. CONCLUSION Scale was found to be a valid and reliable for use with Jordanian men.
Collapse
|
6
|
Leyva B, Persoskie A, Ottenbacher A, Hamilton JG, Allen JD, Kobrin SC, Taplin SH. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2016; 31:693-701. [PMID: 26498649 PMCID: PMC5515087 DOI: 10.1007/s13187-015-0870-8] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Most professional organizations, including the American College of Physicians and U.S. Preventive Services Task Force, emphasize that screening for prostate cancer with the prostate-specific antigen (PSA) test should only occur after a detailed discussion between the health-care provider and patient about the known risks and potential benefits of the test. In fact, guidelines strongly advise health-care providers to involve patients, particularly those at elevated risk of prostate cancer, in a "shared decision making" (SDM) process about PSA testing. We analyzed data from the National Cancer Institute's Health Information National Trends Survey 2011-2012-a nationally representative, cross-sectional survey-to examine the extent to which health professionals provided men with information critical to SDM prior to PSA testing, including (1) that patients had a choice about whether or not to undergo PSA testing, (2) that not all doctors recommend PSA testing, and (3) that no one is sure if PSA testing saves lives. Over half (55 %) of men between the ages of 50 and 74 reported ever having had a PSA test. However, only 10 % of men, regardless of screening status, reported receiving all three pieces of information: 55 % reported being informed that they could choose whether or not to undergo testing, 22 % reported being informed that some doctors recommend PSA testing and others do not, and 14 % reported being informed that no one is sure if PSA testing actually saves lives. Black men and men with lower levels of education were less likely to be provided this information. There is a need to improve patient-provider communication about the uncertainties associated with the PSA test. Interventions directed at patients, providers, and practice settings should be considered.
Collapse
Affiliation(s)
- Bryan Leyva
- Process of Care Research Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr. 3E230, Bethesda, MD, 20892, USA.
| | - Alexander Persoskie
- Basic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Allison Ottenbacher
- Science of Research and Technology Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jada G Hamilton
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Jennifer D Allen
- Department of Public Health and Community Medicine, Tufts University, Boston, MA, USA
| | - Sarah C Kobrin
- Process of Care Research Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr. 3E230, Bethesda, MD, 20892, USA
| | - Stephen H Taplin
- Process of Care Research Branch, Behavioral Research Program, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr. 3E230, Bethesda, MD, 20892, USA
| |
Collapse
|
7
|
Bucay N, Sekhon K, Yang T, Majid S, Shahryari V, Hsieh C, Mitsui Y, Deng G, Tabatabai ZL, Yamamura S, Calin GA, Dahiya R, Tanaka Y, Saini S. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. Oncogene 2016; 36:2667-2679. [PMID: 27893706 PMCID: PMC5426972 DOI: 10.1038/onc.2016.419] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 08/30/2016] [Accepted: 09/30/2016] [Indexed: 12/13/2022]
Abstract
A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region –miR-383- is frequently downregulated in prostate cancer, plays a critical role in determining tumor initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor initiating cells (TICs)/ stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggests that miR-383 regulates PCa tumor initiating/ stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor initiating capacity of CD44+ PCa cells. Also, ‘anti-metastatic’ effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggests that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
Collapse
Affiliation(s)
- N Bucay
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - K Sekhon
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - T Yang
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - S Majid
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - V Shahryari
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - C Hsieh
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - Y Mitsui
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - G Deng
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - Z L Tabatabai
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - S Yamamura
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - G A Calin
- Department of Experimental Therapeutics, Non-Coding RNA Center, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - R Dahiya
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - Y Tanaka
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| | - S Saini
- Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Fransisco, CA, USA
| |
Collapse
|
8
|
Abstract
BACKGROUND The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. METHODS A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. CONCLUSIONS With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
Collapse
Affiliation(s)
- Sharanjot Saini
- Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA.
- University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
9
|
Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A. Family history in the Finnish Prostate Cancer Screening Trial. Int J Cancer 2014; 136:2172-7. [DOI: 10.1002/ijc.29243] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Revised: 08/27/2014] [Accepted: 09/04/2014] [Indexed: 11/06/2022]
Affiliation(s)
- Lasse Saarimäki
- Tampere School of Medicine, University of Tampere; Tampere Finland
| | - Teuvo L. Tammela
- Department of Surgery; Tampere University Hospital and School of Medicine, University of Tampere; Tampere Finland
| | | | - Kimmo Taari
- Department of Urology; Helsinki University Hospital and University of Helsinki; Helsinki Finland
| | - Paula M. Kujala
- Department of Pathology; Fimlab Laboratories, Tampere University Hospital; Tampere Finland
| | - Jani Raitanen
- School of Health Sciences, University of Tampere; Tampere Finland
- UKK Institute for Health Promotion Research; Tampere Finland
| | - Anssi Auvinen
- School of Health Sciences, University of Tampere; Tampere Finland
| |
Collapse
|
10
|
Roberts R. From bench to bedside: the realities of reducing global prostate cancer disparity in black men. Ecancermedicalscience 2014; 8:458. [PMID: 25228914 PMCID: PMC4154941 DOI: 10.3332/ecancer.2014.458] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Indexed: 11/20/2022] Open
Abstract
Prostate cancer in black men of African descent has a different tumour biology compared to those of other races. Its clinical manifestations depict a more aggressive disease with higher morbidity and mortality. This study proposes, through a literature search, identifying applied laboratory and clinical research in prostate cancer directed to improve outcomes and decrease global disparities of prostate cancer in black men of African descent. This review identified five categories pertinent for research: prostate-specific antigen (PSA) testing for early detection and screening, the potential of epigenetics, cultural determinants and health-seeking behaviours, other biomarkers for prostate cancers, and the economics of treating advanced prostate cancer. The analysis revealed that in developed countries, men of African descent are underrepresented in the sampling pools in both laboratory and clinical research, and thus the applicability and relevance of these results to men of African descent are circumspect. However, developing countries with high populations of black males have limited laboratory and clinical research publications. This is due to limited funding to support research programmes and basic clinical services for early detection and treatment. The study concludes that for the involvement of developing countries in bench research, they should do it in collaboration, like fostering partnerships with credible academic-based institutions and organisations. This requires a realm of transparency, respect, protection of the rights and dignity of the patients, and an equity in participation and sharing of the benefits to be accrued. The current transatlantic and Caribbean collaborations in research, education, and health service delivery in prostate cancer care for men of African descent exemplify the successes of such partnerships.
Collapse
Affiliation(s)
- Robin Roberts
- The University of the West Indies School of Clinical Medicine and Research, Princess Margaret Hospital, Shirley Street, P. O. Box GT-2590, Nassau, Bahamas
| |
Collapse
|
11
|
Machtens S, Roosen A, Stief CG, Truß MC. [Prostate biopsy. Update for indication, procedure, and future developments]. Urologe A 2014; 53:1046-51. [PMID: 25023240 DOI: 10.1007/s00120-014-3536-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Transrectal ultrasound-guided prostate biopsy is considered the gold standard in the primary investigation of a suspicious prostate-related finding. The procedure can be carried out with ten probes or more on the lateral side of the prostate, after administering antibiotic prophylaxis and applying local anesthesia. The indication for a biopsy depends on the results of the digitorectal examination, on the serum prostate-specific antigen level, on the individual patient's wish and on his comorbidities. Whether multiparametric imaging should be used before or during the course of a primary or repeated biopsy in order to identify suspicious prostate lesions is the subject of current investigations. Extended biopsy protocols require further clinical investigations before they can become the new standard in the diagnostic work-up. This review delivers an update on the indication for, and technique of, prostate biopsies.
Collapse
Affiliation(s)
- S Machtens
- Klinik für Urologie und Kinderurologie, Marienkrankenhaus Bergisch Gladbach, Dr.-Robert-Koch-Straße 16, 51465, Bergisch Gladbach, Deutschland,
| | | | | | | |
Collapse
|
12
|
Saini S, Majid S, Shahryari V, Tabatabai ZL, Arora S, Yamamura S, Tanaka Y, Dahiya R, Deng G. Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther 2014; 13:1952-63. [PMID: 24817628 DOI: 10.1158/1535-7163.mct-14-0017] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Genomic studies suggest that deletions at chromosome (chr) 5q region (particularly chr5q14-q23) are frequent in prostate cancer, implicating this region in prostate carcinogenesis. However, the genes within this region are largely unknown. Here, we report for the first time the widespread attenuation of miR-3607, an miRNA gene located at chr5q14 region, in prostate cancer. Expression analyses of miR-3607 in a clinical cohort of prostate cancer specimens showed that miR-3607 is significantly attenuated and low miR-3607 expression is correlated with tumor progression and poor survival outcome in prostate cancer. Our analyses suggest that miR-3607 expression may be a clinically significant parameter with an associated diagnostic potential. We examined the functional significance of miR-3607 in prostate cancer cell lines and found that miR-3607 overexpression led to significantly decreased proliferation, apoptosis induction, and decreased invasiveness. Furthermore, our results suggest that miR-3607 directly represses oncogenic SRC family kinases LYN and SRC in prostate cancer. In view of our results, we propose that miR-3607 plays a tumor-suppressive role in prostate cancer by regulating SRC kinases that in turn regulates prostate carcinogenesis. To our knowledge, this is the first report that: (i) identifies a novel role for miR-3607 located in a frequently deleted region of prostate cancer and (ii) defines novel miRNA-mediated regulation of SRC kinases in prostate cancer. Because SRC kinases play a central role in prostate cancer progression and metastasis and are attractive targets, this study has potential implications in the design of better therapeutic modalities for prostate cancer management.
Collapse
Affiliation(s)
- Sharanjot Saini
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Shahana Majid
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Varahram Shahryari
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Z Laura Tabatabai
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Sumit Arora
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Soichiro Yamamura
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Yuichiro Tanaka
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Rajvir Dahiya
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| | - Guoren Deng
- Authors' Affiliation: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California
| |
Collapse
|
13
|
Ross LE, Hall IJ. African american primary care physicians' prostate cancer screening practices. J Prim Care Community Health 2014; 5:36-43. [PMID: 24327595 PMCID: PMC4568547 DOI: 10.1177/2150131913507454] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. African American (AA) men have greater prostate cancer burden than other men. Little is known about AA primary care physicians' (PCPs) practices regarding prostate cancer screening. METHODS We analyzed data from the 2007-2008 National Survey of Primary Care Physicians' Practices Regarding Prostate Cancer Screening. The current study included 604 AA PCPs. Outcomes assessed were (a) offering screening using the prostate-specific antigen (PSA) test, (b) use of screening discussions to involve patients in the decision to screen, and (c) having a discussion policy to try to talk the patient into getting the screening tests. RESULTS Most AA PCPs were male (52%), younger than 50 years (61%), and had 21% to 100% AA patients in their practices (74%). The majority (94%) of AA PCPs offered prostate cancer screening using PSA, discussed the tests with their male patients to involve them in the decision to screen (83%), and had a policy to try to talk the patient into getting the screening tests (77%). Multivariate analysis showed that offering screening, use of discussions, and a usual policy to encourage taking the screening tests varied mainly by practice-related factors, including practice type, practice location, and percentage of AA patients in the practice. CONCLUSION Data from this study indicate that most AA PCPs reported high proscreening behaviors for all 3 outcomes. Additionally, practice- and screening-related factors may be important when examining AA PCP screening behaviors.
Collapse
Affiliation(s)
- Louie E. Ross
- North Carolina A & T State University, Greensboro, NC, USA
| | - Ingrid J. Hall
- Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|
14
|
Martires KJ, Kurlander DE, Minwell GJ, Dahms EB, Bordeaux JS. Patterns of cancer screening in primary care from 2005 to 2010. Cancer 2013; 120:253-61. [DOI: 10.1002/cncr.28403] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2013] [Revised: 08/20/2013] [Accepted: 08/26/2013] [Indexed: 11/09/2022]
Affiliation(s)
- Kathryn J. Martires
- Department of Graduate Medical Education; Scripps Mercy Hospital; San Diego California
- Department of Dermatology; Kaiser Permanente Los Angeles Medical Center; Los Angeles California
| | | | | | - Eric B. Dahms
- Department of Graduate Medical Education; Scripps Mercy Hospital; San Diego California
| | - Jeremy S. Bordeaux
- Case Western Reserve University School of Medicine; Cleveland Ohio
- Department of Dermatology; University Hospitals Case Medical Center; Cleveland Ohio
| |
Collapse
|
15
|
Hall IJ, Ross LE, Taylor YJ, Richardson LC. Primary care physician reports of amount of time spent with male patients in prostate cancer screening discussions. J Prim Care Community Health 2013; 2:192-204. [PMID: 23804801 DOI: 10.1177/2150131911402087] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Major health organizations recommend that physicians discuss the risks and benefits of prostate cancer screening with men before ordering tests. The length of time that health care providers spend discussing prostate cancer screening-related issues with patients has been given little attention. The purpose of this study was to determine the amount of time that primary care physicians (PCP) in the United States reported spending in discussions about prostate cancer screening with patients by selected PCP individual, practice-related, and screening-related factors. METHODS Data were obtained from the 2007-2008 National Survey of Primary Care Physician Practices Regarding Prostate Cancer Screening. We determined whether PCP characteristics were associated with amount of time spent with patients. RESULTS Results showed that female, African American or other race, and older PCP spend more time (above the median) with patients compared to their referents. Also, more time spent with male patients was more often associated with PCP having practices in urban inner city areas as well as when the screening decision was shared between the PCP and the patient/family. CONCLUSION Results from this study offer some insight into the amount of time that PCP report spending with patients in discussing prostate cancer screening-related issues specifically, and confirms the involvement of individual as well as practice-level factors.
Collapse
Affiliation(s)
- Ingrid J Hall
- Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA
| | | | | | | |
Collapse
|
16
|
Tobias-Machado M, Carvalhal GF, Freitas Jr. CH, Reis RBD, Reis LO, Nogueira L, Machado RD, Magnabosco W, Vieira RAC, Mauad EC, Carvalho AL, Faria EF. Association between Literacy, Compliance with Prostate Cancer Screening, and Cancer Aggressiveness: Results from a Brazilian Screening Study. Int Braz J Urol 2013; 39:328-34. [DOI: 10.1590/s1677-5538.ibju.2013.03.05] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 05/13/2013] [Indexed: 11/21/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Eliney F. Faria
- Barretos Cancer Hospital (CHFjr, RDM, WM, RACV, ECM, ALC, EFF)
| |
Collapse
|
17
|
Ko J, Falzarano SM, Walker E, Streator Smith K, Stephenson AJ, Klein EA, Magi-Galluzzi C. Prostate cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart. Prostate 2013; 73:897-903. [PMID: 23280623 DOI: 10.1002/pros.22635] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2012] [Accepted: 12/03/2012] [Indexed: 11/07/2022]
Abstract
BACKGROUND Consensus on prostate cancer (PCA) treatment in older men is currently lacking. We evaluated clinicopathological and oncological outcomes in patients >70-year-old treated with radical prostatectomy (RP). METHODS Clinicopathological and follow-up (FU) data for >70-year-old RP men (2000-2011) were recorded. Association between preoperative features, extraprostatic extension (EPE) and biochemical failure (bF), and postoperative features and bF, was explored. Patients >70-year-old were matched with younger (50- to 70-year-old) men with similar RP features to analyze the effect of age on bF. RESULTS Two hundred eighteen RP patients were >70-year-old. Clinical stage (cT) was T1 in 74.1%. Biopsy (Bx) Gleason score (GS) was 6 (35.8%), 7 (45.9%), and ≥8 (18.3%); RP GS was 6 (10.1%), 7 (63.3%), and ≥8 (26.6%). Median PSAD was 0.14 (range: 0.01-1.12). Pathologic stage (pT) was pT3 in 45.9%. bF occurred in 14.0%. Best preoperative predictive model for pT3 disease included D'Amico risk, number of Bx positive cores, PSAD, maximum % of PCA per core (P < 0.0001); cT, PSAD and primary Bx Gleason pattern best predicted bF preoperatively (P = 0.0031). Among postoperative features, high RP GS, positive margins, and pT3 were significantly associated with bF. Margin status and pT best predicted bF. Patients >70-year-old had 85% higher odds of bF compared to younger men (P = 0.036). CONCLUSIONS PCA detected in >70-year-old men shows adverse pathologic features. Failure rate is significantly higher in older than in matched younger patients.
Collapse
Affiliation(s)
- Jennifer Ko
- Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Gestuvo MK. Health maintenance in older adults: combining evidence and individual preferences. ACTA ACUST UNITED AC 2013; 79:560-78. [PMID: 22976362 DOI: 10.1002/msj.21340] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
There is increasing interest in maintaining health and delaying disability for older adults as this population segment expands. And instead of focusing on a traditional disease-specific approach to health maintenance, there is an ongoing shift to a patient-centered approach, and defining outcomes based on the older adults' goals. In this approach, their goals and preferences are central, and other factors such as their health status and prognosis help determine which goals may be realistic. These subjective goals and objective characteristics are then balanced with the risks, benefits, and harms of established evidence-driven health-maintenance recommendations. Hence, older adults share their goals and preferences with clinicians; while clinicians share information on risks, benefits, harms, and uncertainties of existing health-maintenance recommendations, and help guide the older adult through how existing evidence can respond to their health goals and preferences. In this article, the concept of patient-centered care in the context of health maintenance for older adults is discussed; and health maintenance recommendations for older adults are reviewed.
Collapse
|
19
|
Lippi G, Plebani M. False myths and legends in laboratory diagnostics. Clin Chem Lab Med 2013; 51:2087-97. [DOI: 10.1515/cclm-2013-0105] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 02/26/2013] [Indexed: 11/15/2022]
|
20
|
Moore AD, Hamilton JB, Knafl GJ, Godley PA, Carpenter WR, Bensen JT, Mohler JL, Mishel M. Patient Satisfaction Influenced by interpersonal treatment and communication for African American men: the North Carolina-Louisiana Prostate Cancer Project (PCaP). Am J Mens Health 2012; 6:409-19. [PMID: 22833311 DOI: 10.1177/1557988312443695] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The purpose of this study was to determine if a particular set of health behaviors of health care providers and African American men (AAM) influence patient satisfaction from the AAM's perspective. This descriptive, correlational study consisted of 505 AAM in North Carolina diagnosed with prostate cancer and enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Analyses consisted of bivariate analyses and multiple regression. Patient-to-provider communication, interpersonal treatment, and provider-to-patient communication accounted for 45% (p ≤ .0001) of the variability in patient satisfaction. Interpersonal treatment (provider focusing on the patient) explained the greatest amount (F = 313.53, R² = .39) of patient satisfaction. Since interpersonal treatment focuses on the patient and demonstrated to be the strongest predictor in patient satisfaction, it is noteworthy to consider the emphasis that should be placed on patient-centered care. In addition, knowing important variables positively affecting patient satisfaction provides useful information for developing appropriate interventions to improve AAM health care experiences.
Collapse
Affiliation(s)
- Angelo D Moore
- U.S Army, Tripler Army Medical Center, Honolulu, HI, USA.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Nam RK, Oliver TK, Vickers AJ, Thompson I, Kantoff PW, Parnes HL, Loblaw A, Roth BJ, Williams J, Temin S, Basch E. Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. J Oncol Pract 2012; 8:315-7. [PMID: 23277770 PMCID: PMC3439233 DOI: 10.1200/jop.2012.000715] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/09/2012] [Indexed: 01/02/2023] Open
Affiliation(s)
- Robert K. Nam
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Thomas K. Oliver
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Andrew J. Vickers
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Ian Thompson
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Philip W. Kantoff
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Howard L. Parnes
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Andrew Loblaw
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Bruce J. Roth
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Jim Williams
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Sarah Temin
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Ethan Basch
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; American Society of Clinical Oncology, Alexandria, VA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Harvard Medical School–Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute, Rockville, MD; Washington University in St Louis, St Louis, MO; and Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| |
Collapse
|
22
|
Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012; 30:3020-5. [PMID: 22802323 PMCID: PMC3776923 DOI: 10.1200/jco.2012.43.3441] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Accepted: 05/29/2012] [Indexed: 01/02/2023] Open
Abstract
PURPOSE An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to the ASCO membership after publication or presentation of potentially practice-changing data from major studies. This PCO addresses the role of prostate-specific antigen (PSA) testing in the screening of men for prostate cancer. CLINICAL CONTEXT Prostate cancer is the second leading cause of cancer deaths among men in the United States. The rationale for screening men for prostate cancer is the potential to reduce the risk of death through early detection. RECENT DATA Evidence from a 2011 Agency for Healthcare Research and Quality systematic review primarily informs this PCO on the benefits and harms of PSA-based screening. An update search was conducted to March 16, 2012, for additional evidence related to the topic. RESULTS In one randomized trial, PSA testing in men who would not otherwise have been screened resulted in reduced death rates from prostate cancer, but it is uncertain whether the size of the effect was worth the harms associated with screening and subsequent unnecessary treatment. Although there are limitations to the existing data, there is evidence to suggest that men with longer life expectancy may benefit from PSA testing. Adverse events associated with prostate biopsy are low for the majority of men; however, several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern.
Collapse
Affiliation(s)
- Ethan Basch
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Thomas K. Oliver
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Andrew Vickers
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Ian Thompson
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Philip Kantoff
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Howard Parnes
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - D. Andrew Loblaw
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Bruce Roth
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - James Williams
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| | - Robert K. Nam
- Ethan Basch and Andrew Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas K. Oliver, American Society of Clinical Oncology, Alexandria, VA; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; Philip Kantoff, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Howard Parnes, National Cancer Institute, Rockville, MD; D. Andrew Loblaw and Robert K. Nam, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Bruce Roth, Washington University in St Louis, St Louis, MO; and James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA
| |
Collapse
|
23
|
Consommation du dosage de l’antigène spécifique de la prostate (PSA) en France chez les hommes sans cancer de la prostate déclaré (2008-2010). Bull Cancer 2012; 99:521-7. [DOI: 10.1684/bdc.2012.1580] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
24
|
Ross L, Dark T, Orom H, Underwood W, Anderson-Lewis C, Johnson J, Erwin DO. Patterns of information behavior and prostate cancer knowledge among African-American men. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2011; 26:708-716. [PMID: 21626265 PMCID: PMC3683292 DOI: 10.1007/s13187-011-0241-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The purposes of this study are to explore cancer information acquisition patterns among African-American men and to evaluate relationships between information acquisition patterns and prostate cancer prevention and control knowledge. A random sample of 268 men participated in a statewide interviewer-administered, telephone survey. Men classified as non-seekers, non-medical source seekers, and medical source seekers of prostate cancer information differed on household income, level of education, and beliefs about personal risk for developing prostate cancer. Results from multiple regression analysis indicated that age, education, and information-seeking status were associated with overall levels of prostate cancer knowledge. Results from logistic regression analyses indicated that men who included physicians as one of many information resources (medical source seekers) had superior knowledge over non-seekers and non-medical source seekers on 33% of individual knowledge details. The findings emphasize the need to connect lower-income and lower-educated African-American men to physicians as a source of prostate cancer control information.
Collapse
Affiliation(s)
- Levi Ross
- Office of Cancer Health Disparities Research, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
| | | | | | | | | | | | | |
Collapse
|
25
|
Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 2011; 131:911-23. [DOI: 10.1002/ijc.26462] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2011] [Accepted: 08/31/2011] [Indexed: 11/05/2022]
|
26
|
OKADA H, HOSOKAWA K, MAEDA M. Power-Free Microchip Immunoassay of PSA in Human Serum for Point-of-Care Testing. ANAL SCI 2011; 27:237-41. [DOI: 10.2116/analsci.27.237] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
27
|
Johnson LA, Kanak MA, Kajdacsy-Balla A, Pestaner JP, Bagasra O. Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands. Methods 2010; 52:316-21. [PMID: 20705137 DOI: 10.1016/j.ymeth.2010.08.004] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2010] [Revised: 08/05/2010] [Accepted: 08/06/2010] [Indexed: 11/15/2022] Open
Abstract
Zinc (Zn) is essential for a very large number and variety of cellular functions but is also potentially toxic. Zn homeostasis is therefore dynamically maintained by a variety of transporters and other proteins distributed in distinct cellular and subcellular compartments. Zn transport is mediated by two major protein families: the Zip family, which mediates Zn influx, and the ZnTs which are primarily linked to Zn sequestration into intracellular compartments and are, thereby, involved in lowering cytoplasmic Zn free ion concentrations. In the prostate epithelial cell, the accumulation of high cellular zinc is a specialized function that is necessary for these cells to carry out the major physiological functions of production and secretion of prostatic fluids. The loss of Zn accumulation is the most consistent and persistent characteristic of prostate malignancy. Currently, there are no direct methods to determine the relative Zn levels in various cell types of prostate gland (i.e. stroma, glandular epithelia, acini, and muscular) and no reliable ways to compare the Zn in normal versus malignant areas of the gland. Here we report a new method to show a differential Zn staining method that correlates with various stages of prostate cancer development in situ and expression of a human Zn transporter1-hZIP1 -in situ by in situ reverse transcriptase-polymerase chain reaction hybridization (ISRTPCR) that correlate with the relative Zn levels determined by the differential Zn staining method. By utilizing these methods, we show for the first time that: (1) the relative Zn levels are very low to absent in the malignant glands, (2) normal glands show high Zn levels in both glandular epithelia as well as in stromal tissues, (3) the Zn levels begin to decrease in pre-malignant glands and precedes the development of malignancy, and (4) the expression of human Zn transporter1 (hZIP1) appears to correlate with the Zn levels in the prostate glands and may be the major Zn regulator in this organ.
Collapse
Affiliation(s)
- Leslie A Johnson
- South Carolina Center for Biotechnology, Claflin University, 400 Magniolia Street, Orangeburg, SC 29115, USA
| | | | | | | | | |
Collapse
|